My 25-year-old son Cullen has been trying to deal with trying situations since he was a child. For years he explained to both his parents and medical professionals that something more than asthma or anxiety was making it difficult for him to physically keep up with his friends. A correct…
Read more
A new educational campaign aims to raise awareness of pulmonary arterial hypertension (PAH) symptoms, with the goal of accelerating diagnosis and improving treatment. The American Lung Association campaign has the support of Merck, which markets Winrevair (sotatercept), a medication approved this year in the U.S. and…
Cereno Scientific has secured loan financing to continue developing CS1, its lead therapeutic candidate for pulmonary arterial hypertension (PAH). The funds, totaling at least 250 million Swedish crowns (nearly $23 million), will help the company reach its milestones into 2026. This includes the U.S. Food and Drug Administration…
Get regular updates to your inbox.
